PFE.N
Latest Trade
44.19USDChange
0.24(+0.55%)Volume
3,661,248Today's Range
-
44.7152 Week Range
-
51.86As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 43.95 |
|---|---|
Open | 44.29 |
Volume | 3,661,248 |
3M AVG Volume | 681.37 |
Today's High | 44.71 |
Today's Low | 44.16 |
52 Week High | 51.86 |
52 Week Low | 33.36 |
Shares Out (MIL) | 5,606.69 |
Market Cap (MIL) | 246,414.00 |
Forward P/E | 10.70 |
Dividend (Yield %) | 3.55 |
CDC Statement On ACIP Booster Recommendations
Everest Medicines Announces Approval Of Investigational New Drug Application By China NMPA For SPR206
U.S. CDC Says 212,564,346 Individuals Have Received At Least One Dose Of Covid-19 Vaccine As Of Sept 23
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'amelio
Chief Financial Officer, Executive Vice President - Global Supply
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Lidia Fonseca
Executive Vice President, Chief Technology Officer and Digital Officer
Price To Earnings (TTM) | 20.08 |
|---|---|
Price To Sales (TTM) | 4.44 |
Price To Book (MRQ) | 3.51 |
Price To Cash Flow (TTM) | 14.23 |
Total Debt To Equity (MRQ) | 56.03 |
LT Debt To Equity (MRQ) | 50.48 |
Return on Investment (TTM) | 8.93 |
Return on Equity (TTM) | 7.16 |
Pfizer Inc is in discussions with Singapore's Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.
Sinovac's COVID-19 vaccine is highly effective against serious illness, although rival shots from Pfizer/BioNTech and AstraZeneca showed better protection rates, a large real world study from Malaysia showed.
The U.S. Centers for Disease Control and Prevention (CDC) on Friday backed a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older, some adults with underlying medical conditions and some adults in high-risk working and institutional settings...
* CDC SAYS CDC DIRECTOR ENDORSED ACIP RECOMMENDATION FOR BOOSTER SHOT OF PFIZER-BIONTECH COVID-19 VACCINE IN CERTAIN POPULATIONS
A U.S. CDC advisory panel on Thursday recommended a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions that put them at risk of severe disease.
A U.S. Centers for Disease Control and Prevention advisory panel on Thursday recommended a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions.
The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course, saying breakthrough infections added some urgency to its review.
The European Medicines Agency (EMA) will likely decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course.
The European Medicines Agency (EMA) expects to decide in early October on the possible use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine, a source with direct knowledge of the matter told Reuters.
The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc and BioNTech COVID-19 vaccine for those 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus.
* FDA SAYS AUTHORIZES BOOSTER DOSE OF PFIZER-BIONTECH COVID-19 VACCINE FOR CERTAIN POPULATIONS
The death of a 16-year-old who had a first dose of the Pfizer/BioNTech vaccine against COVID-19 was due to a prior blood clot condition not related to the vaccine, Brazil's health regulator Anvisa said on Wednesday.
Brazil's health regulator Anvisa said on Wednesday that the death of a 16-year-old who got a first dose of the Pfizer/BioNTech vaccine against COVID-19 earlier this month was not related to the vaccine.
The U.S. Food and Drug Administration will authorize a booster dose of the Pfizer Inc and BioNTech COVID-19 vaccine for those aged 65 and older and some high-risk Americans, a Bloomberg News reporter said in a tweet https://twitter.com/LauraLitvan/status/1440797321126563842...
A U.S. Centers for Disease Control and Prevention advisory panel could vote on the use of a third shot of Pfizer Inc and partner BioNTech SE's COVID-19 vaccine on Thursday, an agency official said at a public meeting of the panel on Wednesday.
U.S. Centers for Disease Control and Prevention advisory panel could vote on the use of a third shot of Pfizer Inc and partner BioNTech SE's COVID-19 vaccine on Thursday, an agency official said while kicking off the two-day panel discussion on Wednesday.
* PFIZER CEO ALBERT BOURLA SAYS DECISION TO PROVIDE BOOSTERS SHOULD BE BASED ON SCIENCE – CNBC INTERVIEW Further company coverage:
Britain and South Korea have agreed to swap over 1 million COVID-19 vaccine doses with each other, with the UK sending a first batch of Pfizer shots in the coming weeks and Korea returning the same volume by the end of the year.
The United States plans to donate an additional 500 million COVID-19 vaccines made by Pfizer Inc and BioNTech SE to nations around the world, lifting the total the country is sharing to more than 1 billion doses, according to a source familiar with the plans.
The United States plans to donate an additional 500 million COVID-19 vaccines made by Pfizer Inc and BioNTech SE to nations around the world, lifting the total the country is sharing to more than 1 billion doses, according to a source familiar with the plans.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.